Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $13.86M |
| Gross Profit (TTM) | $11.47M |
| EBITDA | $-78.76M |
| Operating Margin | -600.00% |
| Return on Equity | -121.70% |
| Return on Assets | -51.90% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $0.50 |
| Price-to-Book | 5.34 |
| Price-to-Sales (TTM) | 14.04 |
| EV/Revenue | 10.4 |
| EV/EBITDA | 1.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $63.35M |
| Float | $37.25M |
| % Insiders | 13.60% |
| % Institutions | 32.98% |
Volatility is currently expanding
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination with pembrolizumab in 1L R/M HNSCC on track for the second half of 2026 Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 that support the clinical development of MICVO as both a monotherapy and in combination with pembrolizumab for the treatment of R/M HNSCC Announced the appointment of Nelson Azoulay as Chief Business Officer Expected cash runway into the fourth quarter of 2026 BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2026, and highlighted continued advancement of the micvotabart pelidotin (MICVO) clinical development program. “Our team's exceptional clinical and operational execution in the first quarter of 2026, combined with growing investigator enthusiasm for MICVO's potential to positively impact the lives of patients with cancer, has positioned us to deliver key milestones for the MICVO program this year,” said Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology.
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer.
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC
